News
03-11-2022, 01:10 AM
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
More... (https://www.news-medical.net/news/20220310/Ribociclib-plus-endocrine-therapy-offers-survival-benefit-for-postmenopausal-patients-with-metastatic-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20220310/Ribociclib-plus-endocrine-therapy-offers-survival-benefit-for-postmenopausal-patients-with-metastatic-breast-cancer.aspx)